Back to top
more

NeuroMetrix (NURO)

(Delayed Data from NSDQ)

$3.80 USD

3.80
2,227

+0.25 (6.90%)

Updated Nov 6, 2024 10:15 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for NURO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

NeuroMetrix, Inc. [NURO]

Reports for Purchase

Showing records 1 - 20 ( 65 total )

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 1

01/08/2021

Company Report

Pages: 7

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 2

10/18/2019

Company Report

Pages: 6

Quell Commercial Strategy and Pursuit of Strategic Options Push Platform Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 3

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NURO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 4

04/30/2019

Company Report

Pages: 6

Reported financial results for their Q1/2019

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 5

04/26/2019

Company Report

Pages: 5

Quell Strategy Update May Meaningfully Facilitate Uptake; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 6

01/25/2019

Company Report

Pages: 4

Continue to Believe Both Long-term Prospects and Valuation are Compelling; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 7

12/26/2018

Company Report

Pages: 32

An Underappreciated Commercial Company for Chronic Pain Management; Initiating With Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 8

07/27/2018

Company Report

Pages: 6

Neutral, Gearing up for ?19

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 9

12/03/2017

Company Report

Pages: 4

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 10

10/20/2017

Company Report

Pages: 5

3Q17 Financial Results Reported; Reiterate Buy and Lowering Price Target to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 11

10/03/2017

Company Report

Pages: 6

Neutral - More momentum for Quell, DPNCheck

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 12

07/21/2017

Company Report

Pages: 5

Quell Device and Electrode Shipments Growth Continued in 2Q17; Reiterate Buy and Adjusting Price Target to $10

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 13

07/21/2017

Company Report

Pages: 5

Quell Device and Electrode Shipments Growth Continued in 2Q17; Reiterate Buy and Adjusting Price Target to $10

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 14

06/15/2017

Company Report

Pages: 5

Two New U.S. Patents Issued; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 15

06/15/2017

Company Report

Pages: 5

Two New U.S. Patents Issued; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 16

05/15/2017

Company Report

Pages: 5

One-for-Eight Reverse Split Effected; Reiterate Buy and Adjusting Price Target to $16

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 17

05/15/2017

Company Report

Pages: 5

One-for-Eight Reverse Split Effected; Reiterate Buy and Adjusting Price Target to $16

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 18

05/09/2017

Company Report

Pages: 5

International Patent Expansion Paves Way for Potential Ex-U.S. Commercialization; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 19

05/09/2017

Company Report

Pages: 5

International Patent Expansion Paves Way for Potential Ex-U.S. Commercialization; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuroMetrix, Inc.

Industry: Medical - Products

Record: 20

04/26/2017

Daily Note

Pages: 5

First Quarter Results-Quell Shipments Up 130% YOY

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: GRISEWOOD S

Price: 10.00

Research Provided by a Third Party
// eof